Evidence review
Who Funded the Trial, and Why It Matters
Sponsorship shifts conclusions more than it shifts methods. Where to find the funding line, what the Cochrane evidence measured, and what it did not.
Start with where to look
Three fields, in this order, and it takes about ninety seconds.
The registry record. ClinicalTrials.gov names a lead sponsor and any collaborators, and tags the sponsor with a class — INDUSTRY, NIH, OTHER_GOV, OTHER.
The paper's funding statement. Usually a single line near the end of the abstract, sometimes only in the full text.
The competing-interests statement. This is the one people skip and the one that tells you the most, because it covers the authors rather than the study.
What the evidence actually measured
The Cochrane methodology review on this question pooled 75 papers comparing industry-sponsored drug and device studies with studies funded otherwise1.
Industry-sponsored studies more often had favourable efficacy results: risk ratio 1.27, 95% CI 1.17 to 1.37, from 25 papers, rated moderate-quality evidence1.
They more often had favourable conclusions: risk ratio 1.34, 95% CI 1.19 to 1.51, from 29 papers, rated low-quality evidence1.
For harms the pooled estimate was 1.37, 95% CI 0.64 to 2.93, from four papers, rated very low quality — an interval that comfortably includes no difference1.
Now the half that rarely gets quoted. Comparing industry and non-industry sponsored studies, the review did not find a difference in risk of bias from sequence generation, allocation concealment, follow-up, or selective outcome reporting1.
Read those together and the finding is specific: the gap shows up in results and conclusions, not in the mechanics of randomisation and blinding. Sponsorship is not a reason to assume a trial was run badly. It is a reason to read the conclusion more sceptically than the methods.
Worked example: a 2026 phase 3
Take TRANSCEND-T2D-1, the phase 3 retatrutide monotherapy trial in type 2 diabetes.
The registry lists Eli Lilly and Company as lead sponsor, with no collaborators2.
The publication's funding line names Eli Lilly and Company3.
The competing-interests statement records that six of the ten named authors are employees of and shareholders in Eli Lilly and Company, and that the others report speaker fees, consulting fees or institutional research support from a list of manufacturers3.
Nothing there is hidden, and nothing there is improper — it is the normal structure of late-stage drug development. What it tells you is where to aim your scepticism: at the framing, the choice of comparator, and which endpoint got promoted into the abstract's first sentence. The trial's design was randomised, double-blind and placebo-controlled at 48 sites, and 490 of 537 participants completed on study drug3. That part stands on its own.
Industry money is why the big trials exist
It is worth being blunt about the other side. SELECT randomised 17,604 participants to answer whether semaglutide reduces cardiovascular events, and it was sponsored by Novo Nordisk4.
No public funder was going to write that cheque. A rule of thumb that discards industry-funded evidence discards nearly all of the large, long, hard-endpoint trials in metabolic medicine — see semaglutide and tirzepatide for what those programmes produced.
The useful posture is not distrust. It is asking what the sponsor needed the trial to show, and then checking whether the design gave the result room to come out the other way.
The opposite problem: no sponsor at all
For most compounds sold as peptides, the funding question has a stranger answer, and it is the more important one.
A ClinicalTrials.gov search for CJC-1295 returned one study in August 2026: a phase 2 trial of 120 participants in HIV-associated visceral obesity, lead sponsor ConjuChem, terminated, with a completion date of September 2006 and no results posted5.
That is the entire registered funding history of a compound with a substantial consumer market. Nobody is paying for the definitive trial, which means the definitive trial is not going to appear on its own. An absent sponsor is not neutrality — it is an absent trial.
Academic sponsorship has its own shape
Non-industry does not mean disinterested. Academic sponsors have careers, grant renewals and a strong preference for interesting results.
The tesamorelin literature is a useful case: the pivotal phase 3 was sponsored by Theratechnologies6, while a substantial share of the later mechanistic and liver-fat work was run by academic centres. Both sets are worth reading, and neither is a neutral observer.
The Cochrane review's own scope is a reminder here — it compared industry with non-industry funding and found the difference in results and conclusions, not a clean bill of health for everyone else1.
What to do with the answer
Do not use funding as a verdict. Use it as a place to look harder.
Check the comparator. A favourable result against a weak comparator is a design choice, not a discovery.
Check which endpoint leads the abstract. If the primary endpoint on the registry record is not the number in the headline, ask why — the same trap covered in what a phase 2 result means.
Check whether the results were posted, not just published. That is a separate failure with its own pattern, and it is measurable.
Check whether an independent group has replicated it. Replication by someone with no stake is the only thing that fully retires the question.
Frequently asked questions
Does industry funding mean a trial is unreliable?
No. The Cochrane methodology review of 75 papers found industry-sponsored studies more often had favourable efficacy results (RR 1.27, 95% CI 1.17 to 1.37, moderate-quality evidence) and favourable conclusions (RR 1.34, 95% CI 1.19 to 1.51, low-quality evidence), but found no difference from non-industry studies in sequence generation, allocation concealment, follow-up or selective outcome reporting. The gap is in interpretation, not in the mechanics.
Where do I find who paid for a trial?
Three places: the lead sponsor and collaborator fields on the ClinicalTrials.gov record, the funding statement in the publication, and the competing-interests statement. The last one covers the authors rather than the study and is usually the most informative.
What does it mean when a peptide has no trial sponsor at all?
That nobody has funded the trial that would settle the question. A ClinicalTrials.gov search for CJC-1295 returned one study in August 2026 — a terminated phase 2 in HIV-associated visceral obesity with a 2006 completion date and no posted results. An empty sponsor field is not neutrality; it means the definitive study has no one to pay for it.
Is academically funded research free of this problem?
It has a different one. Academic investigators have grants, careers and a preference for interesting findings. The Cochrane review compared industry with non-industry funding and located a difference; it did not certify non-industry research as unbiased.
References
- Lundh A et al (2017). Industry sponsorship and research outcome. Cochrane Database Syst Rev. https://pubmed.ncbi.nlm.nih.gov/28207928/
- U.S. National Library of Medicine (2023). NCT04881760 — A Study of LY3437943 in Participants Who Have Obesity or Are Overweight. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04881760
- Bajaj HS et al (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. https://pubmed.ncbi.nlm.nih.gov/42250575/
- Lincoff AM et al (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/37952131/
- U.S. National Library of Medicine (2006). NCT00267527 — A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT00267527
- U.S. National Library of Medicine (2013). NCT00123253 — TH9507 in Patients With HIV-Associated Lipodystrophy. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT00123253
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Amylin Analogs: The Next Class After Incretins
An amylin analog has been FDA-approved since 2005. What changed is not the hormone — it is how long the molecule lasts. The trials, in order.
ReadCertificates of Analysis: What They Prove
A COA is a claim about a lot, not a guarantee about a vial. What each test answers, what a purity figure cannot say, and the gap the document never closes.
ReadCompounded Is Not the Trial Drug
A trial tests one defined article: a molecule, a form, a concentration, a container. Compounding changes some of those, and the evidence travels only that far.
Read503A vs 503B: What Is Actually in the Vial
One scheme is inspected against manufacturing standards; the other is not. What each may legally start from, and what the inspection record shows in practice.
ReadGrowth-Hormone Secretagogues: What the Evidence Actually Shows
These compounds reliably raise IGF-1. That is the surrogate. When trials measured function, fracture recovery or disease progression, the results changed.
ReadHealing Peptides and the Gap Between Anecdote and Trial
BPC-157 and TB-500 have thirty years of animal work and a very thin human record. Here is exactly what is registered, what is published, and what neither shows.
ReadHow to Read a ClinicalTrials.gov Record
A registration is a filing, not a review. Fifteen fields, two real peptide records, and the specific places where a record quietly tells you it has stalled.
ReadIncretins Explained: GLP-1, GIP and Glucagon
Three hormones, three receptors, and a class of drugs built on them. What each one does, and why the receptor diagram predicts less than it looks like.
ReadMuscle During Rapid Weight Loss: What Has Been Measured
Roughly a quarter of the weight lost is lean mass — and that was true on placebo too. What the DXA substudies actually show, and how small they are.
ReadOpen-Label vs Blinded: What You Can Conclude
Masking is not a quality score — it decides which explanations a trial can rule out. Five real registry records, and the honest evidence on blinding itself.
ReadOral vs Injectable Peptides: What Changes
One molecule, two routes, one label — and roughly 73 times the milligrams per week. What the gut does to a peptide, and what it costs to get past it.
ReadHalf-Life and Dosing Frequency
From 1.5 minutes to a week, on labels for the same hormone family. Half-life is the number that decides whether a peptide is dosed before meals or once a month.
ReadReconstitution: The Arithmetic, Not the Advice
Concentration is mass divided by volume — except the naive division is wrong, and an FDA label's own numbers prove it. The maths, and what it cannot tell you.
ReadWhat a Phase 2 Result Does and Does Not Tell You
Phase 2 is a dose-finding experiment, not a verdict. Two peptide programmes where the phase 3 exists show exactly which parts of the number survive.
ReadRegistered but Never Reported: The Trials That Vanish
Completed trials that post no results are common and measurable. How to check a compound's registry file, and what the silence does and doesn't tell you.
ReadWhy n=30 Is Not the Same as n=3,000
Enrolment size is not a quality badge — it is precision, and it is the ability to see rare harm. Worked on real peptide trials, with the arithmetic shown.
ReadSurrogate Endpoints vs Outcomes That Matter
Most peptide claims rest on a marker moving, not on anything happening to a person. Two paired trials show what the difference costs to establish.
ReadWhy a Triple Agonist Is Not Simply Better Than a Dual
Adding a receptor adds a mechanism, a side-effect profile, and a reason a trial might read differently. The numbers do not rank the way the labels suggest.
ReadWhat a Peptide Is, and What the Word Hides
Three amino acids or sixty-three thousand daltons — both get called peptides. The definitional confusions that cause the most misreading, settled by labels.
ReadWhat “Research Chemical” Actually Means
The phrase is a sales category, not a regulatory one. What FDA has actually published about seventeen of these peptides, and what the label is doing instead.
ReadHow to Tell a Peptide Claim Is Outrunning Its Evidence
Twelve tells, each with a real case from the registry or the literature. Overstated peptide claims tend to fail on one of them, and usually the same one.
ReadWhat Happens When a Peptide Trial Fails
Four negative results, and what each one killed. A trial can fail an indication, a molecule, a surrogate, or nothing at all — and the difference matters.
ReadWhy Most Peptide Trials Are Small and Short
A registry census, August 2026: one compound has 759 registered studies, another has zero. The reasons are economic, not about whether the drug works.
Read